AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Canavan Disease

Recent research efforts aimed at curing Canavan Disease.

Last updated

Canavan Disease

Overview

Canavan disease is a rare inherited disorder of the brain’s white matter, called a leukodystrophy. It occurs when a child inherits harmful variants in both copies of the ASPA gene, leaving too little of the enzyme aspartoacylase. This causes accumulation of N-acetylaspartate (NAA), a brain chemical, and interferes with the development and maintenance of myelin, the insulating material that helps nerve signals travel efficiently. The typical, more severe form accounts for roughly 85%–90% of cases and usually becomes evident at three to five months of age with poor head control, low muscle tone, developmental delay, and later loss of skills; a smaller atypical group has a more variable and often milder course. GeneReviews: Canavan Disease Natural history study

Canavan disease affects children worldwide and is associated with markedly reduced life expectancy in typical disease, although improved supportive care has extended survival for many children and some people with atypical disease live into adulthood. There is still no approved disease-modifying treatment or cure. Current care is multidisciplinary and supportive: seizure and spasticity management, physical and occupational therapy, nutrition and swallowing support, respiratory and orthopedic care, assistive technology, and educational and family support. GeneReviews: Canavan Disease

Scope of Recent Research (2020–present)

Research has become substantially more clinically focused since 2020, centered on restoring ASPA activity, lowering excess NAA, protecting or rebuilding myelin, and developing biomarkers and functional measures suitable for very small pediatric trials. The field remains small, but it now includes two active phase 1/2 gene-replacement programs, published early human results from one program, and several preclinical strategies designed to treat established—not only presymptomatic—disease. These advances make a durable disease-modifying therapy plausible, but they do not yet establish a curative therapy. rAAV-Olig001-ASPA phase 1/2 results CANaspire trial record

Major Breakthroughs and Emerging Therapies

The leading approach is in vivo gene replacement: delivering a functioning ASPA gene directly to brain cells using an adeno-associated virus (AAV), a modified virus used as a gene-delivery vehicle. In 2025, investigators reported interim results from eight children treated with MYR-101, also called rAAV-Olig001-ASPA, an AAV designed to preferentially reach oligodendrocytes, the myelin-making cells most affected by ASPA deficiency. At 12 months, cerebrospinal-fluid NAA fell significantly, imaging measures of myelination increased, and developmental scores improved; serious adverse events occurred but were judged unrelated to MYR-101 and resolved. These findings are encouraging biological and clinical signals, but the study was small, open-label, and interim, so it cannot yet show that treatment permanently halts or reverses Canavan disease. rAAV-Olig001-ASPA phase 1/2 results

A second gene-replacement model uses systemic AAV9 delivery, intended to distribute the functional ASPA gene more broadly through the central nervous system after an intravenous infusion. An expanded-access report in one child combined intravenous and intracerebroventricular delivery of rAAV9-CB6-ASPA with immune suppression. The child showed lower cerebrospinal-fluid NAA that remained stable through four years of follow-up, increased white-matter myelination, improved motor function, and no typical severe epilepsy by two years. This single-patient experience supports the feasibility of the route and immune-management strategy, but it is not sufficient evidence of general safety or efficacy. Dual-route AAV9 case report

A notable preclinical strategy aims to address both sides of the metabolic problem: restore ASPA while also reducing production of NAA. In symptomatic Aspa-null mice, a dual-function AAV vector that expressed ASPA and suppressed neuronal Nat8l—the gene encoding the NAA-synthesizing enzyme—reversed elevated NAA, brain vacuolation, demyelination, inflammation-related astrocyte activation, weight loss, and movement abnormalities. This approach may widen the treatment window for older children, but it remains a mouse-model result and has not entered human testing. Dual-function AAV study

Researchers are also exploring cell-based repair. In a 2022 study, patient-derived induced pluripotent stem cells (iPSCs) were supplied with normal ASPA using either lentiviral gene transfer or CRISPR/Cas9 gene editing, then converted into neural progenitor cells and transplanted into Canavan-model mice. The cells survived, restored ASPA activity, reduced NAA in brain and cerebrospinal fluid, and improved myelination and motor function. A subsequent study reported that ASPA-expressing human iPSC-derived neural progenitor cells improved NAA, vacuolation, myelination, and motor performance even when transplanted into symptomatic mice. These are important proof-of-concept findings, but cell transplantation has not yet been tested in people with Canavan disease. Corrected iPSC cell-therapy study Symptomatic-mouse iNPC study

Finally, substrate-lowering research has identified another potential target: the astrocyte transporter NaDC3, encoded by SLC13A3. Conditional removal of this transporter in Canavan-model mice reduced brain NAA and improved motor function, suggesting that future small molecules, RNA medicines, or gene-silencing approaches could complement ASPA replacement. This remains an early mechanistic lead rather than a treatment candidate in clinical development. NaDC3 target study

Clinical Trials and Experimental Approaches

Myrtelle sponsors the phase 1/2 CAN-GT study of rAAV-Olig001-ASPA/MYR-101, registered as NCT04833907. The treatment is delivered intracranially to target oligodendrocytes. The 2025 peer-reviewed interim report described the first eight treated children and found reductions in cerebrospinal-fluid NAA, imaging evidence consistent with greater myelination, and improved developmental outcomes at 12 months; longer follow-up and additional participants are needed to determine durability, safety, and functional benefit. rAAV-Olig001-ASPA phase 1/2 results CAN-GT trial record

Aspa Therapeutics, a BridgeBio affiliate, sponsors the recruiting phase 1/2 CANaspire trial of BBP-812, an intravenous AAV9 vector carrying human ASPA, registered as NCT04998396. The ClinicalTrials.gov record was updated on April 17, 2026 and listed the study as recruiting. Company-reported data presented in 2025, rather than a peer-reviewed trial publication, described 14 dosed participants as of December 2024; intravenous infusions were reported as well tolerated, while adverse events and serious adverse events continued to require monitoring. Those preliminary sponsor data should not be interpreted as proof of efficacy until detailed, independently peer-reviewed outcomes and longer-term follow-up are available. CANaspire trial record BBP-812 program update

A separate University of Florida expanded-access, single-patient protocol, NCT05317780, tested simultaneous intravenous and intracerebroventricular rAAV9-CB6-ASPA delivery. Its published case report provides the main outcome evidence for this approach; the registry now lists the expanded-access protocol as no longer available. Single-patient IND record Dual-route AAV9 case report

Methodologies and Scientific Approaches

Canavan researchers combine human natural-history studies with disease-model experiments. Mouse studies use ASPA-deficient models to test whether interventions can prevent disease or reverse established spongy degeneration and myelin loss. Human studies measure NAA in urine or cerebrospinal fluid, magnetic-resonance imaging and spectroscopy markers of white matter and brain water, developmental scales, gross-motor assessments, seizure burden, and caregiver-reported function. Dual-function AAV study rAAV-Olig001-ASPA phase 1/2 results

Biomarker development is especially important because conventional large randomized trials are difficult in an ultra-rare childhood disease. A 2024 natural-history analysis found that urine NAA distinguishes typical from milder Canavan phenotypes and may reflect residual ASPA activity, making it a promising pharmacodynamic marker for therapies intended to restore enzyme function. Researchers have also shown that remote caregiver-assisted motor assessments can be feasible and reliable, potentially reducing the travel burden of future trials. Urine NAA biomarker study Remote motor-assessment study

Leading Institutions and Funding

The clinical gene-therapy effort includes Myrtelle and collaborating investigators at Rowan-Virtua School of Osteopathic Medicine, Dayton Children’s Hospital, Wright State University, and the University of Cincinnati; the published MYR-101 trial was led through this network. Aspa Therapeutics and Massachusetts General Hospital are central to the BBP-812 program and associated natural-history work, with collaborators at University Medical Center Hamburg-Eppendorf, the University of California San Francisco, and the MGH Institute of Health Professions. rAAV-Olig001-ASPA phase 1/2 results Urine NAA biomarker study

Federal support includes National Institute of Neurological Disorders and Stroke grant mechanisms cited in recent Canavan research, including R61/R33 NS119659 and R61 NS136652, as well as the U54 NS115052 Global Leukodystrophy Initiative Clinical Trials Network infrastructure program. Patient organizations remain important funders and conveners: Canavan Research Illinois offers investigator grants through its Max Randell Memorial Fund for the Cure, while the Canavan Foundation tracks the two principal gene-replacement programs and connects families with research opportunities. Canavan therapeutic research review GLIA-CTN program Canavan Research Illinois grants Canavan Foundation research

Strengths, Limitations, and Challenges

The field’s major strength is that Canavan disease has a clear causal target: ASPA deficiency and resulting NAA accumulation. The leading therapies directly address that cause, and early human studies now show that delivered ASPA can lower NAA and produce imaging or motor signals consistent with biological activity. Importantly, mouse studies suggest that combination metabolic correction and ASPA-expressing progenitor cells may improve disease even after symptoms are established. rAAV-Olig001-ASPA phase 1/2 results Dual-function AAV study Symptomatic-mouse iNPC study

The central limitations are the very small, uncontrolled human datasets; differences in delivery route and vector design; and uncertainty about long-term safety, durability, and meaningful functional benefit. Intracranial administration is invasive, while systemic AAV requires careful monitoring for immune and other vector-related effects. Disease severity varies substantially across patients, and the relationship between reduced NAA, improved imaging, and durable gains in daily function still needs validation. Biomarkers and natural-history comparators improve trial interpretability but cannot fully substitute for longer-term clinical evidence. Natural history study Urine NAA biomarker study BBP-812 program update

Outlook and Future Directions

As of September 11, 2026, Canavan disease is closer to a potential disease-modifying treatment than it was in 2020, because ASPA gene replacement has produced preliminary human evidence of target engagement and is being tested in two phase 1/2 programs. However, it is too early to call any approach a cure. The milestones to watch are peer-reviewed BBP-812 outcomes, longer-term MYR-101 follow-up, confirmation that NAA reductions translate into sustained developmental and quality-of-life benefits, and progress of post-symptom combination, substrate-lowering, and cell-based therapies from mice into carefully designed human studies. rAAV-Olig001-ASPA phase 1/2 results CANaspire trial record Corrected iPSC cell-therapy study

References

Don't see your disease? Request a report